Literature DB >> 9827611

Young-onset Parkinson's disease revisited--clinical features, natural history, and mortality.

A Schrag1, Y Ben-Shlomo, R Brown, C D Marsden, N Quinn.   

Abstract

The authors report on clinical features and mortality rates in a group of 149 patients with apparent idiopathic parkinsonism starting before the age of 40 years. Ten had juvenile parkinsonism (JP; onset before age 21 years) and 139 had young-onset Parkinson's disease (YOPD; onset at age 21 to 40 years). Included were 60 patients originally reported 10 years ago. Fifty percent of the JP group had a positive family history of parkinsonism in a first-degree relative, and clinical presentation was heterogeneous. Mortality risk was threefold that of the normal population. In the YOPD group, the mortality risk was double that of the normal population. Poor initial response to L-dopa was a risk factor for early death. In two previously reported patients, the diagnosis had been changed to multiple system atrophy and Machado-Joseph disease. After a median disease duration of 18 years, cognitive impairment was found in only 19% of YOPD patients (13% of those younger than 60 years and 43% of those 60 years or older). Age was the most important factor for development of dementia, but female sex and positive family history of parkinsonism also had more modest predictive value. After a disease duration of 10 years or less, only 5% of patients were experiencing falls and 30% freezing, but all patients had developed L-dopa-related fluctuations and dyskinesias. The authors conclude that the mortality rate in parkinsonism starting before the age of 40 is increased in comparison to the normal population and is similar to the general Parkinson's disease population. Intellectual function and postural reflexes are usually well preserved for many years despite a long history of parkinsonism and the early and frequent occurrence of treatment complications, provided the patients remain biologically and chronologically young.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9827611     DOI: 10.1002/mds.870130605

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  55 in total

Review 1.  Pharmacological treatment of Parkinson's disease.

Authors:  A Münchau; K P Bhatia
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

Review 2.  Juvenile parkinsonism: epidemiology, diagnosis and treatment.

Authors:  Teri R Thomsen; Robert L Rodnitzky
Journal:  CNS Drugs       Date:  2010-06       Impact factor: 5.749

3.  Estimated life expectancy of Parkinson's patients compared with the UK population.

Authors:  Lianna S Ishihara; Anne Cheesbrough; Carol Brayne; Anette Schrag
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-03-30       Impact factor: 10.154

4.  Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson's Disease.

Authors:  Mark Dominic Latt; Simon Lewis; Olfat Zekry; Victor S C Fung
Journal:  Drugs Aging       Date:  2019-03       Impact factor: 3.923

5.  Effects of rTMS on Parkinson's disease: a longitudinal fMRI study.

Authors:  Nadia González-García; Jorge L Armony; Julian Soto; David Trejo; Marco A Alegría; René Drucker-Colín
Journal:  J Neurol       Date:  2011-02-05       Impact factor: 4.849

6.  Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease.

Authors:  Roy N Alcalay; Helen Mejia-Santana; Ming X Tang; Brian Rakitin; Llency Rosado; Barbara Ross; Miguel Verbitsky; Sergey Kisselev; Elan D Louis; Cynthia L Comella; Amy Colcher; Danna Jennings; Martha A Nance; Susan Bressman; William K Scott; Caroline Tanner; Susan F Mickel; Howard F Andrews; Cheryl H Waters; Stanley Fahn; Lucien J Cote; Steven J Frucht; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald Pfeiffer; Laura Marsh; Bradley Hiner; Andrew Siderowf; Ruth Ottman; Lorraine N Clark; Karen S Marder; Elise Caccappolo
Journal:  J Clin Exp Neuropsychol       Date:  2010-02-24       Impact factor: 2.475

7.  Seniors with Parkinson's disease: initial medical treatment.

Authors:  J Eric Ahlskog
Journal:  J Clin Neurol       Date:  2010-12-31       Impact factor: 3.077

Review 8.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

9.  Locomotor response to levodopa in fluctuating Parkinson's disease.

Authors:  Steven T Moore; Hamish G MacDougall; Jean-Michel Gracies; William G Ondo
Journal:  Exp Brain Res       Date:  2007-09-08       Impact factor: 1.972

Review 10.  Parkinson's disease: is the initial treatment established?

Authors:  J Eric Ahlskog
Journal:  Curr Neurol Neurosci Rep       Date:  2003-07       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.